NCT00326118View on ClinicalTrials.gov

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

PHASE3CompletedINTERVENTIONAL
Enrollment

433

Participants

Timeline

Start Date

June 1, 2006

Primary Completion Date

November 1, 2007

Study Completion Date

November 6, 2007

Conditions
Haemophilus Influenzae Type bNeisseria Meningitidis
Interventions
BIOLOGICAL

Haemophilus influenzae type b and meningococcal serogroup C (vaccine)

One intramuscular dose at 12-18 months of age

BIOLOGICAL

Priorix™

One subcutaneous dose at 12-18 months of age

BIOLOGICAL

Hiberix™

One intramuscular dose at 12-18 months of age.

BIOLOGICAL

Meningitec™

One intramuscular dose at 12-18 months of age

Trial Locations (7)

2031

GSK Investigational Site, Randwick

2145

GSK Investigational Site, Westmead

2606

GSK Investigational Site, Garran

3053

GSK Investigational Site, Carlton

4029

GSK Investigational Site, Herston

5006

GSK Investigational Site, North Adelaide

Unknown

GSK Investigational Site, Perth

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY